A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation.

Liu, Yuguo; Luan, Lijuan; Wang, Xingli

Liu, Yuguo; Luan, Lijuan; Wang, Xingli.

Afiliação

Liu Y; Department of Gastrointestinal Surgery, Shandong Tumor Hospital, Jinan, Shandong Province, People's Republic of China.
Luan L; Department of Gastrointestinal Surgery, Shandong Tumor Hospital, Jinan, Shandong Province, People's Republic of China.
Wang X; Department of Gastrointestinal Surgery, Shandong Tumor Hospital, Jinan, Shandong Province, People's Republic of China.

Onco Targets Ther ; 8: 1061-8, 2015.

Article em En | MEDLINE | ID: mdl-25999741

Palavras-chave

FOLFIRI; bevacizumab; metastatic colorectal cancer; panitumumab; second-line chemotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Onco Targets Ther Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google